Andrea M. Murad

Andrea M. Murad

Auto-generated profile, based on publicly available information

Andrea M. Murad

Rogel Cancer Center, University of Michigan, Ann Arbor, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 May 2021 in JNCI Cancer Spectrum
Verified
Journal Article
Open access
PDF file
XFXiao Fan
Xiao Fan
JWJulia Wynn
Julia Wynn
NSNing Shang
Ning Shang
CLCong Liu
Cong Liu
AFAlexander Fedotov
Alexander Fedotov
WCWendy K. Chung
Wendy K. Chung
Unbiased estimates of penetrance are challenging but critically important to make informed choices about strategies for risk management through increased surveillance and risk-reducing interventions. We studied the penetrance and clinical outcomes of 7 breast cancer susceptibility genes (BRCA1, BRCA2, TP53, CHEK2, ATM, PALB2, and PTEN) in almost 13 458 participants unselected for personal or family history of breast cancer. We identified 242 female participants with pathogenic or likely pathogenic variants in 1 of the 7 genes for penetrance analyses, and 147 women did not previously know their genetic results. Out of the 147 women, 32 women were diagnosed with breast cancer at an average age of 52.8 years. Estimated penetrance by age 60 years ranged from 17.8% to 43.8%, depending on the gene. In clinical-impact analysis, 42.3% (95% confidence interval = 31.3% to 53.3%) of women had taken actions related to their genetic results, and 2 new breast cancer cases were identified within the first 12 months after genetic results disclosure. Our study provides population-based penetrance estimates for the understudied genes CHEK2, ATM, and PALB2 and highlights the importance of using unselected populations for penetrance studies. It also demonstrates the potential clinical impact of genetic testing to improve health care through early diagnosis and preventative screening.

7 July 2022 in Journal of Genetic Counseling
Verified
Journal Article
Closed access
ACAllison L. Cirino
Allison L. Cirino
SHStephanie L. Harris
Stephanie L. Harris
AMAndrea M. Murad
Andrea M. Murad
BHBrittany Hansen
Brittany Hansen
JMJennifer Malinowski
Jennifer Malinowski
SCSusan Christian
Susan Christian

22 March 2017 in American Journal of Medical Genetics Part A
Verified
Journal Article
Closed access
PDF file
AMAndrea M. Murad
Andrea M. Murad
MMMelanie F. Myers
Melanie F. Myers
STSusan D. Thompson
Susan D. Thompson
RFRachel Fisher
Rachel Fisher
AAArmand H. Matheny Antommaria
Armand H. Matheny Antommaria

26 April 2025 in Supportive Care in Cancer
Verified
Journal Article
Open access
PDF file
AKAidan M. Kennedy
Aidan M. Kennedy
AMAndrea M. Murad
Andrea M. Murad
EKErika S. Koeppe
Erika S. Koeppe
MRMichelle B. Riba
Michelle B. Riba
ESElena Martinez Stoffel
Elena Martinez Stoffel
MJMichelle F. Jacobs
Michelle F. Jacobs
Purpose: Distress is not routinely measured in patients undergoing cancer genetic counseling. We evaluated the use of the National Comprehensive Cancer Network® (NCCN®) Distress Thermometer (DT) and Problem List (PL) in an unselected population of individuals presenting to a cancer genetics clinic to determine their utility in assessing distress in this population. Methods: Patients presenting to one cancer genetics clinic between April 2019 and March 2020 were asked to complete the DT and PL (2019 version). New patients aged 18 or older were divided into categories of low (DT score < 4) and high distress (DT score ≥ 4), consistent with NCCN groupings for evaluation of distress. Correlates of distress were explored using Chi-square and t tests. Results: Younger age and female sex assigned at birth were associated with reporting high distress. Personal history of cancer was not associated with high distress. Worry, fatigue, and sleep disturbance were the most commonly patient-reported problems. Conclusion: Findings from this study show that the DT can assist in identifying patients undergoing cancer genetic counseling who are experiencing high distress; however, research to develop a PL more specific to the concerns of the oncology genetic counseling patient population may be considered to better identify relevant patient problems.